STOCK TITAN

Bionano Genomics Presented at H.C. Wainwright Global Life Sciences Conference

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary

Bionano Genomics (NASDAQ: BNGO) presented virtually at the H.C. Wainwright Global Life Sciences Conference held on March 9-10, 2021. CEO Dr. Erik Holmlin's presentation is available on-demand on the conference portal and Bionano's investor page for 30 days post-event. Bionano specializes in genome analysis with its Saphyr system, designed for structural variation detection. This platform enables researchers to enhance diagnostics and therapeutic targets. Lineagen, a Bionano subsidiary, has provided over 65,000 genetic tests for neurodevelopmental disorders, including ASD.

Positive
  • Bionano's Saphyr system is engineered for ultra-sensitive structural variation detection, enhancing research capabilities.
  • Lineagen has successfully conducted over 65,000 tests for neurodevelopmental concerns, showcasing service reliability.
Negative
  • None.

SAN DIEGO, March 10, 2021 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced today that company management presented virtually at the H.C. Wainwright Global Life Sciences Conference, which took place March 9-10, 2021. The presentation by Bionano CEO Dr. Erik Holmlin is available on-demand through the H.C. Wainwright conference portal and the Events page in the Investors section of Bionano’s website at https://ir.bionanogenomics.com/. It will be archived on Bionano’s website for 30 days following the event.

About Bionano Genomics
Bionano is a genome analysis company providing tools and services based on its Saphyr system to scientists and clinicians conducting genetic research and patient testing, and providing diagnostic testing for those with autism spectrum disorder (ASD) and other neurodevelopmental disabilities through its Lineagen business. Bionano’s Saphyr system is a research use only platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes, which is known as cytogenetics. The Saphyr system is comprised of an instrument, chip consumables, reagents and a suite of data analysis tools. Bionano provides genome analysis services to provide access to data generated by the Saphyr system for researchers who prefer not to adopt the Saphyr system in their labs. Lineagen has been providing genetic testing services to families and their healthcare providers for over nine years and has performed over 65,000 tests for those with neurodevelopmental concerns. For more information, visit www.bionanogenomics.com or www.lineagen.com.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com 

Investor Relations Contact:
Ashley R. Robinson
LifeSci Advisors, LLC
+1 (617) 430-7577
arr@lifesciadvisors.com 

Media Contact:
Darren Opland, PhD
LifeSci Communications
+1 (617) 733-7668
darren@lifescicomms.com


FAQ

What did Bionano Genomics present at the H.C. Wainwright Conference 2021?

Bionano Genomics presented virtually at the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021.

Where can I find Bionano's conference presentation?

The presentation by CEO Dr. Erik Holmlin is available on-demand on the conference portal and Bionano's investor relations page.

What is the Saphyr system by Bionano Genomics?

The Saphyr system is a genome analysis platform designed for ultra-sensitive detection of structural variations.

How many tests has Lineagen provided for neurodevelopmental disorders?

Lineagen has provided over 65,000 genetic tests for neurodevelopmental disorders.

Bionano Genomics, Inc.

NASDAQ:BNGO

BNGO Rankings

BNGO Latest News

BNGO Stock Data

20.64M
101.81M
0.15%
12.81%
10.25%
Medical Instruments & Supplies
Laboratory Analytical Instruments
Link
United States of America
SAN DIEGO